1933 Industries (TGIF) AI Stock Analysis

• Market Cap: C$4.96M
• Dividend Yield: N/A
• Average Volume (3M): 94.62K
• Price to Earnings (P/E): 13.4
• Beta (1Y): -4.48
• Revenue Growth: -2.30%
• EPS Growth: N/A
• Country: CA
• Employees: 85
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.00
• Shares Outstanding: 495,975,100
• 10 Day Avg. Volume: 87,184
• 30 Day Avg. Volume: 94,616
• PEG Ratio: 0.27
• Price to Book (P/B): -1.07
• Price to Sales (P/S): 0.28
• P/FCF Ratio: 2.94
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 44 Neutral
• Price Target: C$0.01 ▲(0.00% Upside)
• Action: Reiterated Date: 02/25/26
• Date: Action: Reiterated 02/25/26

The score is held down primarily by weak financial resilience (negative equity and meaningful debt) and a declining revenue base despite improving profitability and positive free cash flow. Technicals also lean bearish with the stock trading below key moving averages. Valuation is somewhat supportive (P/E ~9), but does not outweigh the balance-sheet and trend risks.

Positive Factors

Positive free cash flow

Sustained positive operating and free cash flow strengthens operational resilience and funds working capital, modest capex, or debt paydown without external financing. Over 2–6 months this supports creditworthiness and gives management scope to prioritize strategic reinvestment or deleveraging.

Return to profitability

A durable shift to positive net income and operating profit indicates improved cost structure and earnings quality versus prior multi-year losses. If sustained, this supports internal funding for growth, reduces reliance on capital raises, and improves stakeholder confidence over the medium term.

Vertically integrated cannabis model

Vertical integration across cultivation, manufacturing and distribution and a mix of flower and value‑added products enables margin capture, channel flexibility and product diversification. This structural model supports resilience to single-channel shocks and long-term product expansion opportunities.

Negative Factors

Negative shareholders' equity

Negative equity is a persistent solvency flag that constrains access to debt and equity markets, increases default risk, and limits financial optionality. Over months this reduces ability to fund growth or absorb shocks without dilutive or costly financing, pressuring strategic flexibility.

Declining revenue trend

A sustained top-line decline erodes scale economics and makes margin recovery harder; continued revenue shrinkage can quickly reverse recent profitability and free cash flow gains. Without evidence of stabilizing demand, this trend risks longer-term earnings sustainability.

Thin profitability margins

Low net margins provide little buffer against cost increases, pricing pressure, or regulatory/tax changes; modest margin shocks could erase profits. Thin margins also slow internal capital accumulation, limiting reinvestment capacity and prolonging dependence on external funding.

1933 Industries Business Overview & Revenue Model

Company Description

1933 Industries Inc., a cannabis company, engages in the cultivation and production of cannabis products in the United States and Canada. The company produces, packages, and markets of cannabidiol (CBD)-infused products. It operates in the medical and recreational cannabis sectors. The company also offers CBD infused products, such as tinctures, vape pens and cartridges, lotions, pain creams, gummies, and capsules under the Canna Hemp and Canna Hemp X brands. In addition, it provides cannabis flowers and concentrates. The company offers CBD infused products through retail dispensaries, retail outlets, and e-commerce platform. 1933 Industries Inc. was formerly known as Friday Night Inc. and changed its name to 1933 Industries Inc. in September 2018. The company is headquartered in Vancouver, Canada.

How the Company Makes Money

1933 Industries generates revenue through a multi-faceted business model that includes the sale of cannabis products and branded goods. The company operates cultivation facilities to produce high-quality cannabis flower and uses this raw material to create a range of products, including concentrates, edibles, and topicals. It sells these products through both wholesale and retail channels, targeting dispensaries and end consumers. Additionally, 1933 Industries collaborates with other brands and engages in licensing agreements to expand its product offerings and market reach. These partnerships and the company's integrated supply chain contribute significantly to its earnings by ensuring product availability and brand presence in key markets.

1933 Industries Financial Statement Overview

Summary

Operating results show a turnaround with TTM net income turning positive (~$0.5M) and operating profit positive, supported by improved cash generation (TTM operating cash flow ~$2.24M; TTM free cash flow ~$2.07M). However, revenue is contracting (~15.5% TTM decline), margins are thin (net margin ~2.9%), and the balance sheet is a major constraint with negative equity and meaningful debt (~$17–18M), keeping overall financial strength weak.

Income Statement

TTM (Trailing-Twelve-Months) results show a clear profitability inflection: net income turned positive (~$0.5M) versus a loss in FY2025, and operating profit is positive with modest margins (gross margin ~22.7%, net margin ~2.9%). However, the top line is shrinking (TTM revenue down ~15.5%), and profitability remains thin and somewhat volatile historically (large losses in FY2022–FY2023, improving meaningfully in FY2024–FY2025). Overall: improving earnings quality, but the revenue contraction and low margins cap the score.

Balance Sheet

Leverage and capital structure are the key weakness. Stockholders’ equity is negative in the most recent periods (TTM and FY2025), which materially increases financial risk and makes debt-to-equity less meaningful (it is negative due to negative equity). Total debt remains high (~$17–18M) relative to the asset base (~$16–18M recently), leaving limited balance-sheet flexibility despite the recent move back to profitability. Overall: elevated solvency risk and constrained financial optionality drive a low score.

Cash Flow

Cash generation has improved materially. TTM (Trailing-Twelve-Months) operating cash flow is positive (~$2.24M) and free cash flow is positive (~$2.07M), with strong free-cash-flow growth versus FY2025. Free cash flow is also broadly in line with reported earnings in recent periods (TTM free cash flow to net income ~0.92), supporting earnings quality. The main drawback is that operating cash flow covers only a modest portion of debt (TTM ~0.34), so deleveraging capacity is present but not yet strong. Overall: solid recent cash flow momentum with lingering balance-sheet constraints.

Breakdown	Oct 2025	Jan 2025	Oct 2023	Oct 2022	Oct 2021
Income Statement
Total Revenue	17.45M	19.35M	18.27M	12.54M	11.98M
Gross Profit	5.16M	2.94M	-4.22M	2.69M	4.82M
EBITDA	1.01M	313.67K	-10.03M	-13.83M	-2.71M
Net Income	-217.04K	-1.14M	-13.36M	-18.07M	-6.29M
Balance Sheet
Total Assets	16.80M	16.87M	18.02M	29.01M	45.35M
Cash, Cash Equivalents and Short-Term Investments	545.98K	449.18K	1.09M	363.27K	4.41M
Total Debt	17.60M	16.78M	17.57M	17.68M	17.87M
Total Liabilities	21.40M	21.70M	23.28M	21.49M	20.12M
Stockholders Equity	-4.60M	-3.53M	-3.69M	8.52M	25.99M
Cash Flow
Free Cash Flow	1.67M	801.71K	-2.33M	-5.10M	-5.12M
Operating Cash Flow	1.84M	1.69M	-1.53M	-5.09M	-4.67M
Investing Cash Flow	-169.22K	-890.78K	2.33M	1.58K	-456.36K
Financing Cash Flow	-1.58M	-1.46M	-266.55K	1.53M	6.06M

1933 Industries Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BBM	49 Neutral	C$7.43M	-9.82	-167.41%	―	55.74%	-27.59%
TGIF	44 Neutral	C$4.96M	13.38	―	―	-2.30%	―
DHB	44 Neutral	C$5.94M	-3.90	-9.77%	―	13.01%	-2445.45%
PCLO	44 Neutral	C$10.76M	5.19	―	―	15.64%	58.47%
SE	43 Neutral	C$6.59M	-3.18	―	―	-100.00%	-192.62%

1933 Industries Corporate Events

1933 Industries Cuts Debt via Debenture Conversions but Warns on Liquidity Strain

1933 Industries has announced that holders converted $1.035 million of its unsecured 2024 convertible debentures into equity units by the December 22, 2025 deadline, leaving $1.563 million in debentures still outstanding. The conversions have reduced the company’s debt load and bolstered its balance sheet, but management warns that available cash remains tightly constrained and is needed to fund day-to-day operations, meaning the company lacks sufficient liquidity to repay the remaining debentures in cash without jeopardizing business continuity, underscoring ongoing financial pressures despite recently reported positive operating results and net income.

The most recent analyst rating on (TSE:TGIF) stock is a Hold with a C$0.01 price target. To see the full list of analyst forecasts on 1933 Industries stock, see the TSE:TGIF Stock Forecast page.

1933 Industries Extends Profit Streak as Cost Cuts and Debt Buyback Bolster Q1 2026 Results

1933 Industries reported its third consecutive profitable quarter, posting Q1 2026 net income of $139,219 and comprehensive income of $167,249 on revenue of $4.0 million, supported by a gross profit of $1.0 million and a 25% gross margin. The company sharply cut expenses to $0.8 million from $1.9 million a year earlier through cost-saving initiatives, repurchased and cancelled $475,000 in principal value of unsecured convertible debentures at a discount, and saw the expiry of a significant block of stock options and warrants, collectively improving its cost structure and balance sheet while maintaining its position as a top-five cannabis brand in Nevada amid a shifting U.S. regulatory landscape.

1933 Industries Urges Debenture Conversion as U.S. Cannabis Reforms Gather Pace

1933 Industries has issued an urgent reminder to holders of its unsecured 2024 convertible debentures that they must elect to convert on or before December 22, 2025, well ahead of the December 31 maturity date, as stipulated in the debenture agreement. The board has concluded the company cannot repay the debentures in cash without jeopardizing liquidity and business continuity, and is strongly advocating conversion into equity at $0.05 per unit (each unit comprising one common share and one warrant), arguing that this outcome best preserves value for debenture holders and shareholders and reduces the risk of creditor protection proceedings that could leave unsecured creditors with lower recoveries. The company frames the conversion as a key step in strengthening its balance sheet and supporting its operating and growth strategy at a time when the sector may be on the cusp of a more favorable regulatory environment. Management highlights a recent U.S. executive order to reclassify cannabis from Schedule I to Schedule III as a potentially transformative development that could ease tax burdens, improve banking access, and lower administrative costs for cannabis operators, and says it is reassessing its Canna Hemp assets with a view to reintroducing those products to market. 1933 Industries maintains that successful debenture conversion, combined with these regulatory tailwinds, would materially improve liquidity and position the company to capitalize on emerging opportunities in the evolving cannabis landscape.

1933 Industries Urges Debenture Holders to Convert as Maturity Approaches

1933 Industries has announced that its unsecured convertible debentures issued in 2024 will mature on December 31, 2025, urging holders to convert them into equity to strengthen liquidity and support operations. With substantial financial improvements and profitable performance in the past fiscal year, the company aims to reduce financial risk and align debenture holders with equity holders as part of its growth strategy.